808 reports of this reaction
3.3% of all ESKETAMINE HYDROCHLORIDE reports
#6 most reported adverse reaction
DEPRESSION is the #6 most commonly reported adverse reaction for ESKETAMINE HYDROCHLORIDE, manufactured by Janssen Pharmaceuticals Inc.. There are 808 FDA adverse event reports linking ESKETAMINE HYDROCHLORIDE to DEPRESSION. This represents approximately 3.3% of all 24,470 adverse event reports for this drug.
Patients taking ESKETAMINE HYDROCHLORIDE who experience depression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEPRESSION is moderately reported among ESKETAMINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to depression, the following adverse reactions have been reported for ESKETAMINE HYDROCHLORIDE:
The following drugs have also been linked to depression in FDA adverse event reports:
DEPRESSION has been reported as an adverse event in 808 FDA reports for ESKETAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEPRESSION accounts for approximately 3.3% of all adverse event reports for ESKETAMINE HYDROCHLORIDE, making it a notable side effect.
If you experience depression while taking ESKETAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.